
|Articles|July 7, 2003
Second biologic launched for those with A1PI deficiency
Patients with a hereditary form of emphysema caused by alpha-1 proteinase inhibitor (A1PI) deficiency now have another therapeutic option. The FDA recently approved alpha1-proteinase inhibitor (human) [Aralast, Baxter] for chronic augmentation therapy in patients having congenital deficiency of A1PI with clinically evident emphysema. Aralast is currently available exclusively through the specialty pharmacy providers Accredo Health, Caremark, and Coram Healthcare. To obtain more information about Aralast, contact Baxter at (800) 423-2090.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Plant-Based Diet Shows Potential in Active Diabetes Remission
2
How New Federal Spending Bill Bolsters CMS Oversight, PBM Transparency
3
How Pharmacists Reshape Health Care Access and Drive the Future of Patient Care
4
Pharmacy Law Lowdown: Legislative Shifts in 2026 PBM Reform
5






















